Decreased platelet surface expression of P-selectin and activated glycoprotein (GP)IIb/IIIa, in vivo and in response to protease-activated receptor (PAR)-1, PAR-4, and GP VI activation, has been associated with poor OS in patients with cancer 22. This evidence concerns the gene ITGA2B and cancer.